Study identifier:D1441C09906
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Duration of maintenance anti-psychotic therapy after first –episode schizophrenia: a double-blind randomized placebo-control relapse prevention study
schizophrenia
Phase 4
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|